Phase 2 Leukaemia Trial, Recruiting NCT05088226 Sponsor: Chinese PLA General Hospital Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT05088226
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with high-risk acute B cell lymphoblastic leukemia (a type of blood cancer) who have been recommended for a stem cell transplant from a donor
  • People who have a suitable donor available — this could be a matched brother or sister, an unrelated donor who is at least 8 out of 10 markers matched, or a half-matched family member
  • People aged between 12 and 65 years old
  • People whose liver is working well enough, based on blood test results within accepted ranges
  • People whose kidneys are working well enough, based on blood test results within accepted ranges
  • People who do not have any active infections that are not under control, do not have serious organ problems, and do not have severe mental illness
  • People who are well enough to carry out basic daily activities (based on a standard health scoring system, confirm with trial site)
  • People who have read and signed a consent form agreeing to take part

Who may not be able to join:

  • People who are pregnant
  • People with a mental illness or any other condition that would make it difficult to follow the trial's requirements
  • People whose leukemia has a specific genetic marker known as "Philadelphia chromosome positive" (Ph+)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Daihong Liu, Chinese PLA General Hospital

Phone: 86-13681171597

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Chinese PLA General Hospital
Registry
ClinicalTrials.gov
Start date
1 December 2021
Est. completion
1 June 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of participants relapse as assessed by NCCN (National Comprehensive Cancer Network ) criteria

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov